You are here

FDA Approves Erythromycin/Benzoyl Peroxide

FORT COLLINS, Colo., March 30 /PRNewswire-FirstCall/ -- Atrix Laboratories, Inc. (NASDAQ:ATRX) announced today the company received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for 3% erythromycin / 5% benzoyl peroxide (E/BP). In August 2003, the company announced that they had received a non-approval for this product. This approval is a reversal of that previous decision.

Atrix's product is the AB-rated generic to Benzamycin(R) topical gel (3% erythromycin / 5% benzoyl peroxide), which is marketed by Dermik Laboratories. This AB-rated product represents the first approval for a generic version of the popular anti-acne medication. The Novartis company, Sandoz Inc. (formerly Geneva Pharmaceuticals) will market this new E/BP product.

"This is a major victory for Atrix," said David R. Bethune, Atrix's chairman and chief executive officer. "E/BP represented not only great challenges in formulation and in demonstrating clinical bio-equivalency but also represented major regulatory challenges. We are pleased we were able to satisfy the FDA's requirements for approval."

Branded sales of Benzamycin were approximately $41 million for the year ended December 2003.

Source: Atrix Laboratories, Inc.

More Headlines

Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Policy Could Be Life-Changing for People With Spinal Cord Injury
Test Determines Severity of Pain, Helps Physicians Select Best Options
Intratumoral Injection Stimulates Immune Activation
Diabetes and Cancer Patients Could Soon Avoid Injections
Early Cancer Development May Begin in Just 30 Minutes
In Most Cases, Plaque/Tangle Dissolution Occurred Almost Instantly